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Viruses use diff  erent strategies to evade the host 
immune response to establish persistent infection. 
These strategies include generating antibody 
and T cell escape variants as well as actively sup-
pressing the immune system (1–5). In addition, 
neutralizing antibody (nAb) responses to certain 
viral infections are mounted late and  ineffi   ciently 
(2, 6, 7). Lymphocytic choriomen  ingitis virus 
(LCMV) infection in mice is an exemplary 
model characterized by low titers of nAbs, 
which are not detected until at least 60 d after 
infection (2). A similar phenomenon is ob-
served in humans after infection with HIV and 
hepatitis C virus (HCV; references 6, 7). There 
are several possible reasons for the delayed for-
mation of nAb, including immunopathological 
and suppressive eff  ects mediated by T cells 
(5, 8), the prolonged time for affi   nity and avid-
ity maturation of specifi  c antibodies (9), low 
precursor frequency of B cells with neutralizing 
specifi  city (10), and structural features of the 
  viral surface proteins (11, 12). Despite their late 
appearance, nAbs may be important in the 
long-term control of LCMV infection because 
B cell–defi   cient mice cannot control LCMV 
strain WE infection (13).
CD27 is a member of the tumor necrosis 
factor receptor family and acts in a costimula-
tory pathway to elicit T and B cell responses. 
CD27 is expressed on naive and activated CD4+ 
and CD8+ T cells as well as on subsets of B and 
NK cells (14). CD27 signaling activates NF-κB, 
promotes cell survival, enhances TCR-medi-
ated proliferative signals, and increases T cell 
eff  ector function (14, 15). However, persistent 
CD27 signaling leads to T cell depletion (16). 
Thus, CD27 signaling either leads to improved 
T cell function or to T cell dysfunction, prob-
ably depending on the amount, duration, and 
timing of the expression of the CD27 ligand 
CD70 (14, 16). CD70 expression is tightly 
regulated, and it is only transiently expressed 
on activated T and B cells as well as on subsets 
of professional antigen-presenting cells (14). In 
contrast to the very limited expression of CD70 
in normal healthy individuals, there are various 
pathologies with the constitutive expression of 
CD70. For example, the prolonged expression 
of CD70 has been documented in chronic in-
fectious diseases such as HIV (17, 18).
In this study, we have analyzed the role 
of CD27 signaling in the generation of nAb re-
sponses and in virus control after infection with 
LCMV. CD27 signaling on CD4+ T cells 
Elimination of chronic viral infection 
by blocking CD27 signaling
Matthias Matter,1 Bernhard Odermatt,4 Hideo Yagita,5 
Jean-Marc Nuoff  er,2 and Adrian F. Ochsenbein1,3
1Tumor Immunology, Department of Clinical Research, 2Institute of Clinical Chemistry, and 3Institute of Medical Oncology, 
Inselspital, University of Berne, CH-3010 Bern, Switzerland
4Department of Pathology, University Hospital, 8091 Zurich, Switzerland
5Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
Neutralizing antibody (nAb) responses to lymphocytic choriomeningitis virus (LCMV) in 
mice and immunodefi  ciency virus and hepatitis C virus in humans are usually weak and 
slow to develop. This may be the result of structural properties of the surface glycoprotein, 
a low frequency of B cells with neutralizing specifi  city, and the necessity of prolonged 
affi  nity maturation of specifi  c nAbs. In this study, we show that during LCMV infection, 
CD27 signaling on CD4+ T cells enhances the secretion of interferon-𝗄 and tumor necrosis 
factor-𝗂. These infl  ammatory cytokines lead to the destruction of splenic architecture and 
immunodefi  ciency with reduced and delayed virus-specifi  c nAb responses. Consequently, 
infection with the otherwise persistent LCMV strain Docile was eliminated after CD27 
signaling was blocked. Our data provide a novel mechanism by which LCMV avoids nAb 
responses and suggest that blocking the CD27–CD70 interaction may be an attractive 
strategy to prevent chronic viral infection.
CORRESPONDENCE
Adrian F. Ochsenbein: 
adrian.ochsenbein@insel.ch
Abbreviations used: HCV, 
  hepatitis C virus; LCMV, 
  lymphocytic choriomeningitis 
virus; nAb, neutralizing antibody; 
PNA, peanut agglutinin; VSV, 
vesicular stomatitis virus.
The online version of this article contains supplemental material.2146   ELIMINATION OF CHRONIC VIRAL INFECTION | Matter et al.
  increased the secretion of IFNγ and TNFα, leading to the 
destruction of the splenic architecture, including the splenic 
marginal zone. CD27-dependent immunopathological destruc-
tion of lymphatic organs correlated with functional immuno-
suppression and impaired nAb responses. Blocking CD27 
interaction with CD70 by infecting CD27-defi  cient mice or 
by administering a monoclonal αCD70 antibody after infec-
tion reduced immunopathology, and nAb responses were ef-
fi  ciently mounted. As a consequence of the absence of CD27 
signaling, infection with the otherwise persistent LCMV 
strain Docile was eliminated.
RESULTS
nAb responses to viral infections in the absence 
of CD27 signaling
To analyze the role of CD27 signaling in the induction of 
specifi  c B cell responses, we fi  rst infected CD27−/− mice and 
C57BL/6 (BL/6) control mice with vesicular stomatitis virus 
(VSV) Indiana (VSV-IND; Fig. 1 A). After infection with 
VSV-IND, the neutralizing T-independent IgM antibody 
response was comparable in CD27−/− and control mice. 
However, there was a fourfold increase in the T-dependent 
neutralizing IgG antibody titers 8 and 12 d after infection in 
BL/6 mice compared with CD27−/− mice. This slightly en-
hanced switch from IgM to IgG antibodies in BL/6 mice 
suggests a role for CD27 signaling in CD4+ T helper cells. 
However, nAbs in CD27−/− mice reached comparable titers 
with those in BL/6 mice 20 d after infection, and all CD27−/− 
mice survived VSV infection without developing lethal pa-
ralysis. Therefore, in agreement with earlier fi  ndings in infl  u-
enza infection (19), our results indicate that CD4+ T helper 
cell–dependent and –independent B cell responses are largely 
independent of CD27.
nAb responses to LCMV infection in mice are low and 
are only mounted late after infection (2). Surprisingly, 
CD27−/− mice mounted high nAb responses starting 20–30 d 
after infection with LCMV-WE, whereas BL/6 mice had 
antibody titers below the detection limit (Fig. 1 B). In addi-
tion to the virus-specifi  c antibody response, LCMV infection 
polyclonally activates B cells that are not virus specifi  c, lead-
ing to hypergammaglobulinemia (20). A recent study sug-
gested an inverse correlation between CD4+ T cell– dependent 
polyclonal B cell activation and the induction of nAb in 
LCMV infection (21). However, polyclonal B cell activation 
and hypergammaglobulinemia was even enhanced in the 
  absence of CD27 signaling when compared with controls 
(Fig. 1 B).
Our fi  nding suggested an important inhibitory role of CD27 
signaling in the generation of LCMV-specifi  c nAb responses. 
Figure 1.  Primary immune response against VSV-IND and LCMV-WE. 
(A) nAbs after VSV-IND infection of CD27−/− and BL/6 mice. (B) CD27−/− 
and BL/6 mice were infected with LCMV-WE and total serum Ig, and LCMV-
WE–specifi  c nAbs were measured. Data in A and B are expressed as the 
mean ± SEM of n = 3–5 mice and are representative of two (A) to fi  ve 
(B) individual experiments except for total serum Ig, which is the mean of 
pooled sera of fi  ve mice per group. (C) Number of CD70+ cells within 
CD4+, CD8+, CD11c+, and CD19+ splenocytes after LCMV-WE infection 
determined by fl  ow cytometry. Mean ± SEM (error bars) of n = 3 mice. 
  Numbers in parentheses indicate the percentage (mean ± SEM) of CD70-
expressing cells at the peak of expression (day is indicated).
Figure 2.  Induction of CTL response and virus elimination in 
CD27−/− mice. (A) CTL activity (51Cr release assay) 8 d after LCMV-WE 
infection. Closed symbols, gp33-pulsed target cells; open symbols, un-
pulsed target cells. (B and C) The absolute number of Db-gp33–specifi  c 
CD8+ T cells measured by tetramer staining (B) and virus titer (C) were 
assessed in the spleen after LCMV-WE infection. (D) Cytokine production 
of purifi  ed P14 and P14 × CD27−/− T cells 8 d after adoptive transfer to 
BL/6 recipients and LCMV-WE infection. Data are expressed as the mean 
± SEM (error bars) of n = 3–4 animals and are representative of one of 
two individual experiments. ns, P ≥ 0.05.JEM VOL. 203, September 4, 2006  2147 
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Therefore, we analyzed the expression of the CD27   ligand 
(CD70) in the spleen at diff  erent time points after infection of 
BL/6 or CD27-defi  cient mice with LCMV-WE. CD70 was 
expressed for a prolonged time on CD4+ and CD8+ T cells and 
on CD19+ B cells (Fig. 1 C). In addition, CD70 was detectable 
on a few dendritic cells at days 8 and 15 after infection.
Normal CTL induction and expansion in the absence of CD27
Titers of nAb against LCMV increased when CD8+ T cell 
function was absent (2). This increase may be caused by 
enhanced viral replication. We recently showed that CTL 
induction after infection with 200 pfu LCMV-WE was 
independent of CD27 signaling (22). Comparably, pri-
mary CTL function after infection with 106 pfu LCMV-
WE, as analyzed by the direct lysis of peptide-pulsed target 
cells and the absolute number of gp33-specifi  c T cells, was 
not impaired in CD27−/− mice (Fig. 2, A and B). More 
importantly, both CD27−/− and control mice eliminated 
the virus within 12–16 d after infection from the spleen, 
lung, liver, and kidney (Fig. 2 C and Fig. S1, available at 
Figure 3.  Spleen architecture after LCMV-WE infection. (A and B) 
BL/6 and CD27−/− mice and CD27−/− mice receiving purifi  ed CD4+ T cells 
from BL/6, IFNγ−/−, or TNFα−/− mice were infected with LCMV-WE. 8 d after 
infection, the spleen was analyzed. (A) Cryosections stained for   metallophilic 
marginal zone macrophages (MOMA-1), follicular dendritic cell (4C11) net-
works, PNA+ germinal center clusters, surface IgM+ B cells, and CD21+CD35+ 
marginal zone B cells. (B) The relative frequency of CD21+CD35+IgM+IgD− 
marginal zone B cells and of CD21−CD35−IgM+IgD− T1B cells among total 
lymphocytes and their absolute number per spleen are shown. (C) The relative 
frequency of CD19+ B cells among total lymphocytes and their abso-
lute number per spleen are shown. Horizontal bars indicate gates for CD19+ 
B cells. One representative section or dot plot out of n = 3–9 mice per group 
is shown. Numbers indicate the mean. Numbers of marginal zone B cells 
and T1B cells in BL/6 mice or CD27−/− mice receiving CD4+ T cells from BL/6, 
IFNγ−/−, or TNFα−/− mice were compared with CD27−/− mice. *, P < 0.05; 
ns, P ≥ 0.05.2148   ELIMINATION OF CHRONIC VIRAL INFECTION | Matter et al.
http://www.jem.org/cgi/content/full/jem.20060651/DC1). 
We next compared the production of infl  ammatory cyto-
kines by LCMV gp33 TCR transgenic P14 and P14 x 
CD27−/− CD8+ T cells 8 d after infection with LCMV-WE 
and found similar levels of IFNγ and TNFα (Fig. 2 D). 
Therefore, CTL responses to LCMV infection were normal 
in the absence of CD27, and diff  erences in viral control 
did not explain the more effi   cient generation of nAb in 
CD27−/− mice.
CD27-dependent immunopathology
The induction of antibody and T cell responses against viral 
infections requires that the anatomical structures of secondary 
lymphoid organs are intact (23). During LCMV infection, 
the splenic architecture is disrupted, and the marginal zone 
and germinal centers are destroyed (8). Therefore, we ana-
lyzed the splenic architecture 8 d after infection with LCMV-
WE in CD27−/− and BL/6 mice. Naive BL/6 (Fig. 3, A and 
B) and CD27−/− mice (not depicted but identical to naive 
BL/6 mice) had a normal splenic architecture with an intact 
marginal zone and germinal centers. LCMV infection of 
BL/6 mice induced the destruction of the marginal zone and 
germinal centers and a complete absence of follicular den-
dritic cells (Fig. 3 A). Flow cytometry analysis further revealed 
that marginal zone B cell (CD21+CD35+IgM+IgD−) numbers 
were decreased in LCMV-infected BL/6 mice when com-
pared with noninfected BL/6 mice (Fig. 3 B). Surprisingly, 
the splenic architecture remained largely intact after LCMV 
infection of CD27−/− mice, and infected mice had clearly 
identifi  able germinal centers containing follicular dendritic 
cells and a preserved marginal zone (Fig. 3 A).
In addition, fl  ow cytometry analysis demonstrated that 
relative (percentage) and absolute numbers of marginal zone 
B cells (CD21+CD35+IgM+IgD−) were higher in LCMV-
infected CD27−/− than in BL/6 mice (Fig. 3 B). The fre-
quency (percentage) and absolute numbers of transitional 
type 1 B cells (T1B; CD21−CD35−IgM+IgD−) were higher 
in LCMV-infected CD27−/− mice. However, this only reached 
statistical signifi  cance if analyzed as the percentage of total 
lymphocytes (Fig. 3 B). In contrast, relative and absolute 
numbers of CD19+ B cells (Fig. 3 C) and mature IgM+IgD+ 
B cells in the spleen (16.4 × 106 for CD27−/− vs. 17.4 × 106 
for BL/6) were similar in LCMV-infected CD27−/− and 
BL/6 mice. In summary, LCMV-induced immunopathology 
is dependent on CD27 signaling.
CD27 signaling on CD4+ T cells induces immunopathology 
and suppression of nAbs
To identify the cell population responsible for the CD27-de-
pendent reduction in nAb responses, purifi  ed BL/6 CD8+ or 
CD4+ T cells were adoptively transferred to CD27−/− recip-
ient mice before infection with LCMV-WE. The adoptive 
transfer of CD8+ T cells to CD27−/− mice did not aff  ect the 
nAb response (Fig. 4 A). In contrast, the transfer of purifi  ed 
CD27-expressing CD4+ T cells to CD27−/− mice resulted in 
a reduction and delay in the nAb response when compared 
with CD27−/− controls (Fig. 4 A). Likewise, the adoptive 
transfer of CD4+ T cells from BL/6 to CD27−/− mice 
  resulted in immunopathology comparable with BL/6 mice 
as analyzed by immunohistochemistry and fl  ow cytometry 
(Fig. 3, A and B).
The constitutive expression of CD70 on B cells in trans-
genic mice induced IFNγ production by T cells, which led 
to a depletion of the CD70-expressing B cells (24). Thus, 
we analyzed the role of CD27 signaling on the secretion of 
infl   ammatory cytokines by LCMV gp13 TCR transgenic 
SMARTA and SMARTA × CD27−/− CD4+ T cells 8 d af-
ter infection with LCMV-WE (Fig. 4 B). The production of 
Figure 4.  Characterization of the cell population responsible for 
reduced antibody production. (A) BL/6 and CD27−/− mice and CD27−/− 
mice receiving purifi  ed CD4+ or CD8+ T cells from BL/6 mice were in-
fected with LCMV-WE, and nAbs were measured. (B) Cytokine production 
by purifi  ed SMARTA and SMARTA × CD27−/− T cells 8 d after adoptive 
transfer to BL/6 recipients and LCMV infection. *, P < 0.05; ns, P ≥ 0.05. 
(C) BL/6 and CD27−/− mice and CD27−/− mice receiving purifi  ed CD4+ 
T cells from BL/6, IFNγ−/−, or TNFα−/− mice were infected with LCMV-WE, 
and nAbs were measured 80 d later. (D) CD27−/− mice receiving purifi  ed 
CD4+ T cells from BL/6, IFNγ−/−, or TNFα−/− mice were infected with 
LCMV-WE, and, 8 d after adoptive transfer, the total number of 
CD27+CD4+ T cells per spleen were determined by fl  ow cytometry. All 
results are shown as the mean ± SEM (error bars) of n = 3 animals per 
group and are representative of two independent experiments.JEM VOL. 203, September 4, 2006  2149 
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IL-6, -1β, and -10 was independent of CD27, whereas the 
secretion of IFNγ and TNFα was decreased in the absence of 
CD27 signaling on specifi  c  CD4+ T cells. To determine 
whether the secretion of IFNγ and TNFα by CD4+ T cells 
is important in the induction of immunopathology and the 
suppression of nAb responses, CD4+ T cells from BL/6, 
IFNγ−/−, and TNFα−/− mice were adoptively transferred to 
CD27−/− recipients before infection with LCMV-WE. The 
transfer of CD4+ T cells from IFNγ−/− and TNFα−/− mice 
to CD27−/− recipients infected with LCMV-WE did not af-
fect specifi  c nAb responses (Fig. 4 C). Similarly, the adoptive 
transfer of CD4+ T cells from IFNγ−/− or TNFα−/− mice to 
CD27−/− recipients before LCMV-WE infection had little 
eff  ect on immunopathology (Fig. 3, A and B).
Earlier studies with B cells constitutively expressing CD70 
have shown that ligation of CD70 by CD27 and consequent 
reverse signaling through CD70 can lead to a reduction of 
antibody secretion (25, 26). Therefore, the enhanced nAb 
response against LCMV-WE in CD27−/− mice may be 
caused by the absence of inhibitory signals mediated by CD70 
signaling. To address this possibility, we assessed the number 
of CD27-expressing CD4+ T cells in CD27−/− recipients af-
ter the adoptive transfer of CD4+ T cells of BL/6, IFNγ−/−, 
and TNFα−/− mice (Fig. 4 D). In this experimental setup, 
the CD27-expressing transferred CD4+ T cells are the only 
cells that provide CD70 ligation. CD4+ T cells from BL/6, 
TNFα−/−, or IFNγ−/− mice similarly engrafted in recipient 
mice, and, therefore, a comparable CD27–CD70 interaction 
was provided by the transferred cells. Despite this similar 
CD27–CD70 ligation in recipient mice, only the transfer of 
CD4+ T cells from BL/6 mice impaired antibody produc-
tion, whereas the transfer of CD4+ T cells from IFNγ−/− or 
TNFα−/− mice did not. This largely excludes the possibility 
that reverse signaling through CD70 reduces the production 
of nAb. Therefore, we conclude that CD27 ligation on 
CD4+ T cells contributes to the secretion of IFNγ and 
TNFα, leading to immunopathology with delayed specifi  c 
nAb responses.
LCMV-induced immunosuppression of nAb responses 
to viral coinfections
LCMV infection has been shown to induce an acquired 
  immunodefi  ciency with reduced nAb responses and increased 
susceptibility to coinfection with VSV (21, 27). To elucidate 
whether CD27-dependent immunopathology also impairs 
antibody responses to unrelated antigens, we infected mice with 
VSV New Jersey (VSV-NJ) 8 d after LCMV-WE infection. 
BL/6 mice immunized with LCMV-WE and coinfected with 
VSV-NJ had a slight reduction in the nAb IgM response, 
whereas the switch to IgG was virtually absent (Fig. 5 A). In 
contrast, the nAb response to VSV-NJ was not impaired in 
LCMV-infected CD27−/− mice.
Similar results were obtained after challenging LCMV-
infected CD27−/− and BL/6 mice with UV-inactivated 
VSV-NJ (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20060651/DC1). In addition, VSV-NJ only 
abortively replicates in immunocompetent mice and was 
eliminated similarly in LCMV-infected CD27−/− and BL/6 
mice (Fig. S2). These controls exclude the possibility that 
diff  erences in VSV replication in CD27−/− and BL/6 mice 
account for the observed diff   erences in nAb responses. 
  Although LCMV-infected BL/6 mice and CD27−/− mice pos-
sess similar numbers of B cells (Fig. 3 C), it may be possible 
that B cells with VSV-neutralizing specifi  city may have been 
eliminated by the CD27–CD70 interaction during LCMV 
infection. To analyze this, purifi   ed B cells from VSV-IgM 
transgenic mice crossed on a μMT background (T11μMT; 
reference 28) were transferred to BL/6 and CD27−/− mice 
Figure 5.  LCMV-induced suppression of the nAb response to viral 
coinfections induced by CD4+ cells. (A) CD27−/− and BL/6 mice were 
infected with LCMV-WE, coinfected 8 d later with VSV-NJ, and VSV-NJ 
nAbs were determined. (B) BL/6 (IgMb+) and CD27−/− (IgMb+) mice re-
ceiving purifi  ed CD19+ B cells from T11μMT (IgMa+) mice were infected 
with LCMV-WE. 8 d after adoptive transfer, the total number of VSV-
specifi  c B cells (CD19+IgMa+IgMb−) were determined in the spleen by 
fl  ow cytometry. (C) BL/6, CD27−/−, and CD27−/− mice receiving purifi  ed 
CD4+ or CD8+ T cells from BL/6 mice were infected with LCMV-WE. 8 d 
later, mice were coinfected with VSV-NJ, and VSV-NJ nAbs were deter-
mined. (D) BL/6, CD27−/−, and CD27−/− mice receiving purifi  ed CD4+ 
T cells from BL/6, IFNγ−/−, or TNFα−/− mice were infected with LCMV-
WE. 8 d later, mice were coinfected with VSV-NJ, and VSV-NJ nAbs were 
determined 20 d later. All experiments are shown as means ± SEM 
(error bars) of n = 3–6 animals per group and are representative of two 
independent experiments.2150   ELIMINATION OF CHRONIC VIRAL INFECTION | Matter et al.
before infection with LCMV-WE (Fig. 5 B). A comparable 
number of B cells with VSV-neutralizing specifi  city 8 d later 
excluded the possibility that the observed reduction of 
VSV nAbs in LCMV-immune mice coinfected with VSV 
was caused by a reduced number of VSV-specifi  c B cells in 
the presence of a functional CD27–CD70 interaction in 
BL/6 mice.
We also tested whether the adoptive transfer of BL/6 
CD4+ T cells to CD27−/− recipients aff  ected the nAb re-
sponse in mice fi  rst infected with LCMV and coinfected 8 d 
later with VSV-NJ. In these mice, there was an impaired 
switch to VSV-NJ–specifi  c IgG antibodies (Fig. 5 C). Mice 
receiving CD8+ T cells did not have an impaired antibody 
response (Fig. 5 C). Similar to the impaired nAb response to 
LCMV infection, the reduced nAb to coinfection with VSV-
NJ was mediated by IFNγ and TNFα. The transfer of CD4+ 
T cells from IFNγ−/− and TNFα−/− mice to CD27−/− re-
cipients infected with LCMV and coinfected with VSV did 
not reduce the production of specifi  c nAb as much as CD4+ 
T cells from BL/6 mice (Fig. 5 D). Therefore, CD27 liga-
tion on CD4+ T cells contributes to the secretion of IFNγ 
and TNFα, leading to virus-induced immunodefi  ciency 
with impaired antibody responses to related and unrelated 
viral antigens.
Blocking CD27 signaling eliminates an otherwise persistent 
infection with LCMV-Docile
Infection with the LCMV strain Docile establishes chronic 
infection in mice with the functional exhaustion of specifi  c 
CTLs and no nAb response (29). This model of persistent in-
fection was used to analyze the physiological role of CD27 and 
CD4+ T cell–dependent immunopathology and immunodefi  -
ciency. After the infection of BL/6 mice with LCMV-Docile, 
nAb titers were below the detection level, and the virus estab-
lished persistent infection (Fig. 6, A and B). In contrast, 
CD27−/− mice mounted nAb within 20–30 d after infection, 
and high titers were reached 50 d after infection (Fig. 6 A). 
CD27−/− mice were also able to control and eliminate LCMV-
Docile infection in the blood (Fig. 6 B) and organs within 60 d 
(Fig. 6 C). In contrast, high viral titers were found in BL/6 
mice in all organs analyzed up to 100 d after infection (Fig. 6, 
B and C). Antibody-defi  cient JH
−/− and CD27−/− × JH
−/− 
mice did not control LCMV-Docile infection, indicating that 
nAbs were crucial for virus control (Fig. 6, A and B).
8, 20, and 40 d (not depicted) after the infection of 
CD27−/− and BL/6 mice with LCMV-Docile, only a few 
LCMV gp33-specifi  c CTLs were detectable by tetramer stain-
ing (Fig. 6 E). CTL function, as analyzed by the lysis of pep-
tide-pulsed target cells or by intracellular IFNγ staining, was 
also impaired in BL/6 and CD27−/− mice 8 and 40 d after in-
fection (Fig. 6, D and E). These results indicate that specifi  c 
CTLs were functionally exhausted or anergic. Surprisingly, 
after the elimination of LCMV-Docile, CD27−/− mice re-
gained a functional CTL response to LCMV gp33 and np396 
(not depicted), as documented in a 51Cr release cytotoxicity 
assay (Fig. 6 D) or by intracellular IFNγ staining (Fig. 6 E).
Figure 6.  Control of chronic viral infection in CD27−/− mice. 
(A–E) CD27−/−, BL/6, JH
−/−, and CD27−/− × JH
−/− mice were infected 
with LCMV-Docile. (A) LCMV-Docile–specifi  c nAb. (B and C) Virus titer in 
peripheral blood (B) and different organs (days 8, 40, and 100 after injec-
tion; C). (D) Spleen cells tested in a 51Cr release assay directly ex vivo 
(day 8 after injection; left) or after restimulation in vitro for 5 d (day 40 
after injection, middle; and day 100 after injection, right). Closed symbols, 
gp33-pulsed target cells; open symbols, unpulsed target cells. Symbols 
in A–D represent the mean ± SEM of n = 3–8 mice. (E) Spleen cells ana-
lyzed for Db-gp33–specifi  c T cells measured by tetramer staining and 
intracellular IFNγ production after gp33 stimulation. The cells’ frequen-
cies among CD8+ T cells are indicated. One representative dot plot 
from one mouse out of three is shown. Numbers indicate means ± SEM 
(error bars) of n = 3 mice. The experiment was repeated once with 
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We next wanted to determine whether blocking CD27 
signaling could be a therapeutic approach to prevent chronic 
viral infection. Because CD70 expression peaked 8 d after 
infection on CD8+ T cells and even later on B and CD4+ T 
cells (Fig. 1 C), we decided to test CD70 blockade several 
days after infection. BL/6 mice infected with LCMV-Docile 
were treated for 5 wk with a blocking monoclonal antibody 
to CD70 (FR70; reference 30) starting 4 d after infection. 
LCMV-Docile was detectable in all animals at day 4 after in-
fection, with 1.3 × 105 (± 0.02 × 105) pfu/ml in the blood. 
Similar to the results obtained in CD27−/− mice, treatment 
with the blocking mAb to CD70 elicited a nAb response and 
resulted in reduced viral titers (Fig. 7, A and B). 
Interestingly, immunohistochemistry and analysis of B cell 
subpopulations by fl  ow cytometry revealed that the splenic 
architecture was largely restored in BL/6 mice 35 d after 
LCMV-Docile infection in spite of virus persistence (Fig. 8, 
A and B). Nevertheless, no nAbs were produced in BL/6 
mice even up to 100 d after infection (Fig. 6 A). This may be 
explained by the fact that no functional IFNγ-producing 
LCMV-specifi  c CD4+ T cells were detectable 35 d after in-
fection, probably as a result of exhaustion or anergy (Fig. 8 C; 
reference 31). In addition, CD70 expression was low to non-
detectable 35 d after infection with LCMV-Docile (unpub-
lished data). Therefore, it was not surprising that treating 
LCMV-Docile–infected mice from day 35 to 60 after in-
fection with mAb to CD70 neither induced protective nAb 
responses nor eliminated the virus (Fig. 8, D and E). In sum-
mary, these results suggest that the kinetics of CD70 expres-
sion and CD4+ T cell function determine the time frame in 
which blocking CD27 signaling effi   ciently eliminates chronic 
viral infections.
D  I  S  C  U  S  S  I  O  N 
The induction of nAbs represents a central protective mecha-
nism of the immune system and is the basis of most currently 
available vaccines. Unfortunately, attempts to improve pro-
tective antibody responses against persisting viruses such as 
HIV in humans or LCMV in mice have repeatedly failed (12, 
32). Diff  erent mechanisms may contribute to the ineffi   cient 
generation of nAbs. For LCMV, one study (12) showed that 
Figure 7.  Blocking CD27–CD70 signaling after infection. (A and B) 
BL/6 mice were infected with LCMV-Docile and treated with αCD70 mAb 
or control Ig. (A) LCMV-Docile–specifi  c nAbs were determined. Symbols 
represent the mean ± SEM (error bars) of n = 3–5 mice. (B) Virus titer 
was measured 66 d after infection in the spleen. The horizontal bars rep-
resent the mean.
Figure 8.  Blocking CD27 signaling during chronic infection. (A and B) 
BL/6 mice were infected with LCMV-Docile, and, 35 d after infection, the 
spleen was analyzed. (A) Cryosections stained for metallophilic marginal 
zone macrophages (MOMA-1), follicular dendritic cell (4C11) networks, 
PNA+ germinal center clusters, surface IgM+ B cells, and CD21+CD35+ 
marginal zone B cells. One representative section or dot plot from 1 out 
of 3 mice/group is shown. (B) Relative frequency among total lympho-
cytes and absolute number of CD21+CD35+IgM+IgD− marginal zone B 
lymphocytes per spleen. Numbers indicate the mean. (C) BL/6 mice were 
infected with LCMV-Docile. At the indicated time points, splenocytes were 
restimulated in vitro with p13 and analyzed for CD4+ T cells that produce 
IFNγ intracellularly. (D and E) BL/6 mice were infected with LCMV-Docile 
and treated with αCD70 mAb or control Ig from day 35 to day 60 after 
infection. (E) LCMV-Docile–specifi  c nAb. Virus titer in the spleen 66 d after 
infection. (C and D) Data are shown as the means ± SEM (error bars) of 
n = 3 animals. (E) The horizontal bars represent the mean.2152   ELIMINATION OF CHRONIC VIRAL INFECTION | Matter et al.
the kinetics of nAb responses are crucially dependent on in-
trinsic factors of the surface antigen and that LCMV glyco-
protein expressed on the immunogenic VSV backbone did 
not induce LCMV-specifi  c nAb. In addition, B cells with a 
receptor of neutralizing specifi  city against LCMV may exist 
at very low frequencies and may only be generated by sub-
stantial somatic hypermutation. More potent LCMV-specifi  c 
nAb responses in mice genetically engineered to express 
LCMV-neutralizing B cell receptors argue in favor of such 
mechanisms (10). In this study, we defi  ne an additional and 
novel mechanism by which a virus avoids the effi   cient pro-
duction of nAb to establish persistent infection. The virus-
induced expression of CD70, which was mainly on B and T 
cells, resulted in CD27-dependent destruction of the splenic 
architecture and suppression of nAb responses.
Intact secondary lymphatic organ structure is important 
in the generation of antibody responses (23). The marginal 
zone and marginal zone B cells seem to be important in the 
initiation of antibody responses against blood-borne patho-
gens (33, 34). We found that the splenic marginal zone and 
germinal centers were virtually absent and that numbers of 
marginal zone B cells were reduced in BL/6 mice during 
acute LCMV infection. Immunopathology in the spleen was 
provoked by IFNγ and TNFα secreted by CD4+ T cells. 
Moreover, CD27 ligation on LCMV-specifi  c CD4+ T cells 
increased the secretion of IFNγ and TNFα, suggesting that 
CD27-dependent immunopathology is induced by the in-
creased secretion of these infl  ammatory cytokines. This con-
clusion is supported by the observation that B cell numbers in 
CD70 transgenic mice progressively decrease in primary and 
secondary lymphoid organs as a result of the CD27-induced 
production of IFNγ by T cells (24). Likewise, cytokines that 
bind to receptors for TNF and IFN type I or type I/II are in-
volved in the destruction of the splenic architecture after re-
petitive CpG treatment (35). TNFα as well as IFNγ have 
cytotoxic action when secreted in the vicinity of target cells 
(36). In addition, IFNγ may render cells more sensitive to 
TNFα-induced apoptosis (37). Similarly, a TNFα-dependent 
destruction of splenic architecture has been observed after 
Leishmania infection (38). Recent data have suggested that 
after Leishmania infection, the TNFα-mediated loss of stro-
mal cells leads to the reduced production of CCL19 and 
CCL21, which are both important for maintenance of the 
marginal zone (39).
Interestingly, it has been demonstrated that B cells are cru-
cial for the maintenance of the splenic marginal zone and that 
the depletion of B cells in a Cre/lox P system resulted in de-
struction of the integrity of the marginal zone (40). In our 
study, LCMV infection resulted in a selective depletion of 
marginal zone B cells and T1B cells without reducing the 
number of other B cell subsets or total B cells. Therefore, the 
destruction of the splenic architecture and marginal zone after 
LCMV infection is not caused by reduced total B cell 
numbers. However, the destruction of the splenic architecture 
may be initiated indirectly by the elimination of B cell subsets, 
macrophages, or stromal cells, which provide chemokines, 
integrin ligands, and receptors that are important for the 
splenic architecture (39, 41, 42).
LCMV infection has been shown to induce an acquired 
immunosuppression with temporally impaired antibody re-
sponses to viral coinfections (21, 27). Preservation of the 
splenic architecture after LCMV infection in CD27−/− mice 
also enhanced the nAb response to coinfection with VSV. This 
indicates that CD27-dependent destruction of the splenic 
  architecture causes a general immunodefi  ciency, resulting in 
impaired nAb responses against both LCMV and unrelated 
viral coinfections. In addition, as a result of polyclonal B cell 
activation, 90% of the antibodies produced after LCMV in-
fection are not specifi  c for the virus (20). This hypergamma-
globulinemia is also observed after HIV and HCV infections 
(18, 43). Because polyclonal B cell activation is dependent on 
B cell–T cell interactions (20), the preservation of the splenic 
architecture in CD27-defi  cient mice facilitated this interac-
tion and augmented hypergammaglobulinemia.
This study provides evidence that blocking the CD27–
CD70 interaction may be an attractive strategy to prevent 
chronic infection after virus inoculation. This fi  nding was 
surprising because, as outlined in the Introduction, diff  erent 
mechanisms, including structural aspects of LCMV glycopro-
tein, contribute to the delayed and ineffi   cient generation of 
nAbs. The time frame in which blocking CD27 signaling re-
duces immunopathology and improves antibody responses 
may be dependent on characteristics of the viral infection, 
such as replication kinetics and infectious dose. For LCMV 
infection, we showed that CD70 is expressed at high levels 
up to 20 d after infection. At later time points, CD70 was no 
longer detectable, and the splenic architecture was restored. 
Therefore, in this infectious model, αCD70 mAb treatment 
had to be started during acute infection and was ineffi   cient 
when started 35 d after infection. Nevertheless, αCD70 mAb 
treatment was effi   cient when started several days after infec-
tion at a time point when LCMV replicated to high titers and 
was clearly detectable in blood samples.
Further studies will be necessary to evaluate whether our 
fi  ndings can be generalized to other types of viral infections 
that are characterized by a late and ineffi   cient induction of 
nAbs, such as HIV and HCV (6, 7). In analogy to LCMV, 
structural factors of the surface glycoproteins limit the effi   -
cient induction of nAb against HIV (4, 44). Furthermore, the 
frequency of B cells with neutralizing B cell receptors to HIV 
is low, probably as a result of cross-reactivity to self-antigens, 
leading to the depletion of specifi  c B cells from the reper-
toire (45). Interestingly, CD70 is overexpressed on B cells and 
T cells in active HIV infection, suggesting a possible role for 
this costimulatory molecule in the induction of immunopa-
thology and suppression (17, 18). In fact, immunopathology 
of the splenic architecture with the reduction of marginal 
zone B cells has been shown in HIV infection (46).
In summary, blocking CD27 interaction is a novel strategy 
for therapeutically infl  uencing persistent virus infections by 
reducing immunopathology and acquired immunosuppres-
sion and, thereby, enhancing nAb production. Our fi  ndings JEM VOL. 203, September 4, 2006  2153 
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may aff  ect the treatment of clinically relevant chronic infec-
tions that are characterized by the delayed production of nAbs 
in conjunction with the prolonged expression of CD70.
MATERIALS AND METHODS
Mice. BL/6 mice were obtained from Harlan, and CD27−/− (47) mice 
were obtained from the Netherlands Cancer Institute. SMARTA (48), 
P14 (49), T11μMT (28), and JH
−/− (50) mice were obtained from the 
  Institute for Laboratory Animals (Zurich, Switzerland), and TNFα−/− 
(51) mice were obtained from C. Müller (Division of Immunopathology, 
University of Berne, Bern, Switzerland). IFNγ−/− (B6.129S7-Ifngtms1Ts) 
was purchased from the Jackson ImmunoResearch Laboratories. All animal 
experiments were performed with 6–8-wk-old age- and sex-matched mice 
at the central animal facility of the University of Berne (Bern, Switzerland) 
and were approved by the Experimental Animal Committee of the Canton 
of Berne.
Viruses and peptides. LCMV-WE and -Docile isolates were obtained 
from R.M. Zinkernagel (Institute of Experimental Immunology, University 
of Zurich, Zurich, Switzerland) and were propagated in L929 fi  broblasts and 
Madin–Darby canine kidney cells, respectively. Mice were infected i.v. with 
106 pfu of LCMV-WE or 2 × 107 pfu LCMV-Docile in all experiments. 
VSV-IND and VSV-NJ isolates were obtained from R.M. Zinkernagel and 
were grown in BHK21 cells. Mice were infected i.v. with 2 × 106 pfu VSV-
IND or -NJ in all experiments. For UV inactivation, VSV-NJ was irradiated 
(G15W; Osram Sylvania) for 30 s at a distance of 5 cm in a thin layer of liquid 
in a 35-mm petri dish. UV inactivation was tested in a focus-forming assay. 
The LCMV glycoprotein peptide amino acids gp33 (KAVYNFATM), 
np396 (FQPQNGQFI), and p13 (G  L  N  G  P  D  I  Y  K  G  V  Y  Q  F  K  S  V  E  F  D  ) were 
purchased from NeoMPS SA.
Detection of virus and nAb titers. The detection of LCMV virus titer 
and nAbs has been described previously (21, 52). Neutralizing total (IgM and 
IgG) and IgG antibodies to VSV as well as virus titer were measured as 
  described previously (23).
51Cr release assay. 51Cr release assays directly ex vivo or after restimulation 
in vitro were performed as described previously (23).
Administration of 𝗂CD70. Mice were treated i.p. with 300 μg αCD70 
(FR70; reference 30) twice a week from day 4 until day 35 or from day 
35 until day 60. Rat IgG (Sigma-Aldrich) was used as a control.
Immunohistochemistry. Freshly removed organs were immersed in Hank’s 
balanced salt solution and snap frozen in liquid nitrogen. Tissue sections of 
5-μm thickness were cut in a cryostat and treated as described previously 
(23). Tissue sections were stained with rat monoclonal antibodies against the 
following antigens: IgM (clone R6-60.2), CD21/35 (clone 7G6), follicular 
dendritic cells (clone FDC-M1; all from BD Biosciences), and metallophilic 
marginal zone macrophages (MOMA-1; BMA Biomedicals AG). Lectin 
staining of follicular center cells was performed with biotinylated peanut 
  agglutinin (PNA; Vector Laboratories) followed by preformed alkaline 
phosphatase–labeled avidin–biotin complexes (DakoCytomation).
Flow cytometry. All antibodies were obtained from eBioscience except 
MHC class I (H-2Db) tetramers complexed with gp33 or np396, which were 
purchased from ProImmune, and αVα2,  αCD21/35, and αIgD, which 
were obtained from BD Biosciences. For intracellular staining, lymphocytes 
(106/well) were stimulated for 5 h with gp33 or np396 peptide (10−6 M/
well) in the presence of recombinant 25 U/ml IL-2 and 5 μg/ml brefeldin 
A (Sigma-Aldrich). Cells were stained for surface molecules, fi  xed with 4% 
paraformaldehyde, and cell membranes were permeabilized with Perm buf-
fer (PBS, 2% FCS, 5 mM EDTA, 0.1% saponin, and 0.2% NaN3) and stained 
with αIFNγ-FITC. Relative fl  uorescence intensities were measured using a 
fl  ow cytometer (FACScan or BD LSRII; Becton Dickinson) and analyzed 
using FlowJo software (Tree Star). Sorting of live cells was performed using 
a fl  ow cytometry system (FACSVantage; Becton Dickinson).
Cytokine measurement. 106 SMARTA or SMARTA × CD27−/− sple-
nocytes were injected i.v. into BL/6 recipients that were immunized on the 
following day with LCMV-WE. 8 d after infection, CD4+Vα2+ T cells 
were sorted by fl  ow cytometry, and 3 × 105 CD4+Vα2+ T cells were culti-
vated with 5 × 105 gp13-pulsed and irradiated (1,500 rad) naive BL/6 sple-
nocytes in a 96-well plate in a total of 200 μl IMDM supplemented with 
10% FCS for 16 h. 120 μl of the supernatant was harvested and analyzed for 
cytokines using a mouse Fluorokine MAP Multiplex Assay (R&D Systems). 
An identical experimental setup was used to analyze cytokine secretion by 
P14 and P14 × CD27−/− splenocytes except that harvesting was performed 
after 6 h of cultivation.
Adoptive transfer of CD4+ and CD8+ cells. CD4+ and CD8+ T cells 
were purifi  ed by MACS (Miltenyi Biotec) using αCD4 or αCD8 magnetic 
beads. 107 CD4+ or CD8+ T cells were injected i.v. into CD27−/− mice that 
were infected on the same day with LCMV-WE.
Adoptive transfer of CD19+ B cells of T11μMT mice. CD19+ B cells 
were purifi  ed by MACS (Miltenyi Biotec) using αCD19 magnetic beads. 
5 × 106 CD19+ B cells were injected i.v. into CD27−/− and BL/6 mice, 
which were then infected with LCMV-WE.
Serum protein electrophoresis. Total serum immunoglobulin was 
  detected by capillary zone electrophoresis using an electrophoresis system 
(Paragon CZE 2000; Beckman Coulter), and total serum protein was mea-
sured on an analyzer (model 917; Hitachi) according to the Biuret method.
Statistical analysis. Statistical comparison between groups was performed 
with a two-tailed unpaired Student’s t test using Prism 4 software (GraphPad 
Software). Data was considered statistically signifi   cant when the p-value 
was <0.05.
Online supplemental material. Fig. S1 shows the control of LCMV-WE 
in the absence of CD27 signaling in the lung, kidney, and liver. Fig. S2 pre-
sents the nAb response to nonreplicating VSV-UV and replication of VSV-
NJ in LCMV-WE–infected mice. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20060651/DC1.
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